fax: (206) 744-9858
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial†
Version of Record online: 26 JUL 2006
Copyright © 2006 American Association for the Study of Liver Diseases
Volume 44, Issue 2, pages 360–367, August 2006
How to Cite
Morishima, C., Morgan, T. R., Everhart, J. E., Wright, E. C., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Lok, A. S. F., Bonkovsky, H. L., Di Bisceglie, A. M., Lee, W. M., Dienstag, J. L., Ghany, M. G. and Gretch, D. R. (2006), HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial. Hepatology, 44: 360–367. doi: 10.1002/hep.21265
Potential conflicts of interest: Of the authors who have financial relationships with Hoffmann-La Roche, Inc., Timothy R. Morgan is on the speakers' bureau and receives research support; Herbert L. Bonkovsky is a consultant, on the speakers' bureau, and receives research support; Mitchell L. Shiffman is a consultant, on the speakers' bureau, and receives research support; Gregory T. Everson is a consultant, on the speakers' bureau, and receives research support; Karen L. Lindsay is a consultant and receives research support; Anna S. F. Lok is a consultant and receives research support; Adrian M. Di Bisceglie is a consultant, on the speakers' bureau, and receives research support; and William M. Lee is on the speakers' bureau and receives research support. The authors who have other financial relationships related to this project are Chihiro Morishima, David R. Gretch, Herbert L. Bonkovsky, and William M. Lee, who receive research support from Bayer Diagnostics. The authors with no financial relationships related to this project are James E. Everhart, Jules L. Dienstag, and Marc G. Ghany.
This is publication number 16 from the HALT-C Trial Group.
- Issue online: 26 JUL 2006
- Version of Record online: 26 JUL 2006
- Manuscript Accepted: 11 MAY 2006
- Manuscript Received: 2 MAR 2006
- National Institute of Diabetes & Digestive & Kidney Diseases. Grant Numbers: N01-DK-9-2326, N01-DK-9-2324, N01-DK-9-2319, N01-DK-9-2327, N01-DK-9-2320, N01-DK-9-2321, N01-DK-9-2325, N01-DK-9-2323, N01-DK-9-2322, N01-DK-9-2318, N01-DK-9-2328
- National Institute of Allergy and Infectious Diseases (NIAID)
- National Cancer Institute
- National Center for Minority Health and Health Disparities
- General Clinical Research Center grants from the National Center for Research Resources, National Institutes of Health. Grant Numbers: M01RR-06192, M01RR-01066, M01RR-00051, M01RR-00827, M01RR-00633, M01RR-00043, M01RR-00042, M01RR-00065
- Hoffman-La Roche, Inc.
- Cooperative Research and Development Agreement (CRADA) with the National Institutes of Health
- 2NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002; 19: 1–46.
- 15Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol 2001; 96: 2968–2972., , , , , , et al.Direct Link:
- 19Comparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatment of HCV infections. J Clin Microbiol 2005; 43: 2590–2597., , , , .